{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:49:05Z","timestamp":1790995745355,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic disorder characterized by unpredictable attacks of angioedema. MENTALIST (UnMEt Needs in herediTAry angioedema\u2014a gLobal physIcian perSpecTive) is the first international survey uncovering unmet needs and identifying barriers to optimal management in HAE following the latest update of the World Allergy Organization (WAO)\/European Academy of Allergy and Clinical Immunology (EAACI) HAE guidelines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This web-based survey comprised 24 questions on HAE management and unmet needs. HAE-expert physicians from the Angioedema Centers of Reference and Excellence network ranked unmet needs according to their own perspectives and their patients\u2019 perspectives, using a 10-point Likert scale ranging from 0 (not a challenge\/unmet need at all) to 10 (huge challenge\/unmet need).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of 64 respondents from 32 countries, most (91%) had &gt;\u20095 years of experience in managing HAE. Overall, 48% of respondents (<jats:italic>n<\/jats:italic>\u2009=\u200931\/64) reported that &lt;\u200950% of their patients had achieved the WAO\/EAACI HAE treatment goals of total disease control and \u201cnormalization\u201d of life at the time of the survey. Implementation of consensus recommendations was found to be inconsistent across regions. Gaps in non\u2013HAE-expert physician knowledge, treatment costs, and reimbursement for long-term prophylaxis were the highest-priority challenges according to the respondents. Burden of disease remains a challenge among patients, as reported by their physicians.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The MENTALIST findings highlight a need for removal of barriers to HAE treatment goals and propose a call to action to improve access to treatments, for greater provision of education for physicians and patients, critical collaboration with patient organizations and industry stakeholders and ultimately to optimize HAE care.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03739-8","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T15:28:39Z","timestamp":1753716519000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Unmet needs in hereditary angioedema: an international survey of physicians"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9389-1767","authenticated-orcid":false,"given":"Thomas","family":"Buttgereit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Aulenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Adatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Vera","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam Ali","family":"Al-Nesf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Altrichter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abuzakouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Al-Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramzy Mohammed","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Boccon-Gibod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Bouillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Brussino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Bare\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula J.","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Betschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herberto","family":"Chong-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar Calder\u00f3n","family":"Llosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Dorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9rgio Duarte Dortas","family":"Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Fomina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie Shen","family":"Fok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anete S.","family":"Grumach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Greve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Guilarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Gon\u00e7alo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Grivcheva-Panovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Hide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Hakl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur","family":"Jindal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance H.","family":"Katelaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailajah","family":"Kamaleswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Kinaciyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Latysheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ignacio Larco","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n Lleonart","family":"Bellfill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Mobayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasa T.","family":"Mitrevska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Nicola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio Alberto Salvador","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Porebski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonny","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Paes Leme","family":"Ferriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson Rosario","family":"Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00fclent Enis","family":"\u015eekerel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faradiba Sarquis","family":"Serpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Stobiecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Trainotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Valerieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chamard","family":"Wongsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane C. Y.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Yucel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinglei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Nenci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Magerl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip H.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"issue":"7","key":"3739_CR1","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/all.15214","volume":"77","author":"M Maurer","year":"2022","unstructured":"Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Aygoren-Pursun E, et al. The international WAO\/EAACI guideline for the management of hereditary angioedema\u2013the 2021 revision and update. Allergy. 2022;77(7):1961\u201390.","journal-title":"Allergy"},{"issue":"1","key":"3739_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13023-018-0815-5","volume":"13","author":"E Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2018","unstructured":"Aygoren-Pursun E, Magerl M, Maetzel A, Maurer M. Epidemiology of bradykinin-mediated angioedema: a systematic investigation of epidemiological studies. Orphanet J Rare Dis. 2018;13(1):73.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3739_CR3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13023-024-03265-z","volume":"19","author":"X Guan","year":"2024","unstructured":"Guan X, Sheng Y, Liu S, He M, Chen T, Zhi Y. Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review. Orphanet J Rare Dis. 2024;19(1):256.","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 1","key":"3739_CR4","doi-asserted-by":"publisher","first-page":"S08","DOI":"10.2500\/aap.2020.41.200050","volume":"41","author":"WR Lumry","year":"2020","unstructured":"Lumry WR, Settipane RA. Hereditary angioedema: epidemiology and burden of disease. Allergy Asthma Proc. 2020;41(Suppl 1):S08-S13.","journal-title":"Allergy Asthma Proc"},{"issue":"2","key":"3739_CR5","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jaci.2024.03.024","volume":"154","author":"A Reshef","year":"2024","unstructured":"Reshef A, Buttgereit T, Betschel SD, Caballero T, Farkas H, Grumach AS, et al. Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus. J Allergy Clin Immunol. 2024;154(2):398\u2013411.","journal-title":"J Allergy Clin Immunol"},{"key":"3739_CR6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2147\/JAA.S398333","volume":"16","author":"D Jones","year":"2023","unstructured":"Jones D, Zafra H, Anderson J. Managing diagnosis, treatment, and burden of disease in hereditary angioedema patients with normal C1-esterase inhibitor. J Asthma Allergy. 2023;16:447\u201360.","journal-title":"J Asthma Allergy"},{"issue":"3","key":"3739_CR7","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.anai.2020.10.009","volume":"126","author":"MA Riedl","year":"2021","unstructured":"Riedl MA, Banerji A, Gower R. Current medical management of hereditary angioedema: follow-up survey of US physicians. Ann Allergy Asthma Immunol. 2021;126(3):264\u201372.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"3739_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s13023-020-01570-x","volume":"15","author":"K Bork","year":"2020","unstructured":"Bork K, Machnig T, Wulff K, Witzke G, Prusty S, Hardt J. Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence. Orphanet J Rare Dis. 2020;15(1):289.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3739_CR9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s13023-020-01506-5","volume":"15","author":"M Magerl","year":"2020","unstructured":"Magerl M, Gothe H, Krupka S, Lachmann A, Ohlmeier C. A Germany-wide survey study on the patient journey of patients with hereditary angioedema. Orphanet J Rare Dis. 2020;15(1):221.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3739_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13223-023-00795-2","volume":"19","author":"J Mendivil","year":"2023","unstructured":"Mendivil J, DerSarkissian M, Banerji A, Diwakar L, Katelaris CH, Keith PK, et al. A multicenter chart review of patient characteristics, treatment, and outcomes in hereditary angioedema: unmet need for more effective long-term prophylaxis. Allergy Asthma Clin Immunol. 2023;19(1):48.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"6","key":"3739_CR11","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.anai.2020.02.018","volume":"124","author":"A Banerji","year":"2020","unstructured":"Banerji A, Davis KH, Brown TM, Hollis K, Hunter SM, Long J, et al. Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States. Ann Allergy Asthma Immunol. 2020;124(6):600\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"3739_CR12","doi-asserted-by":"publisher","first-page":"100758","DOI":"10.1016\/j.waojou.2023.100758","volume":"16","author":"HJ Chong-Neto","year":"2023","unstructured":"Chong-Neto HJ. A narrative review of recent literature of the quality of life in hereditary angioedema patients. World Allergy Organ J. 2023;16(3):100758.","journal-title":"World Allergy Organ J"},{"issue":"1","key":"3739_CR13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s12016-021-08897-8","volume":"62","author":"FG Minafra","year":"2022","unstructured":"Minafra FG, Gon\u00e7alves TR, Alves TM, Pinto JA. The mortality from hereditary angioedema worldwide: a review of the real-world data literature. Clin Rev Allergy Immunol. 2022;62(1):232\u20139.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"3739_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2500\/aap.2021.42.210001","volume":"42","author":"Y Cao","year":"2021","unstructured":"Cao Y, Liu S, Zhi Y. Recurrent and acute abdominal pain as the main clinical manifestation in patients with hereditary angioedema. Allergy Asthma Proc. 2021;42(2):131\u20135.","journal-title":"Allergy Asthma Proc"},{"issue":"3","key":"3739_CR15","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.2500\/aap.2021.42.210029","volume":"42","author":"TJ Craig","year":"2021","unstructured":"Craig TJ, Banerji A, Riedl MA, Best JM, Rosselli J, Hahn R, et al. Caregivers\u2019 role in managing hereditary angioedema and perceptions of treatment-related burden. Allergy Asthma Proc. 2021;42(3):S11\u20136.","journal-title":"Allergy Asthma Proc"},{"issue":"1","key":"3739_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13223-021-00563-0","volume":"17","author":"J Hews-Girard","year":"2021","unstructured":"Hews-Girard J, Goodyear MD. Psychosocial burden of type 1 and 2 hereditary angioedema: a single-center Canadian cohort study. Allergy Asthma Clin Immunol. 2021;17(1):61.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"1","key":"3739_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13023-021-01717-4","volume":"16","author":"J Mendivil","year":"2021","unstructured":"Mendivil J, Murphy R, de la Cruz M, Janssen E, Boysen HB, Jain G, et al. Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey. Orphanet J Rare Dis. 2021;16(1):94.","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"3739_CR18","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1016\/j.jaip.2023.03.032","volume":"11","author":"LM Fijen","year":"2023","unstructured":"Fijen LM, Klein PCG, Cohn DM, Kanters TA. The disease burden and societal costs of hereditary angioedema. J Allergy Clin Immunol Pract. 2023;11(8):2468\u201375.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"3739_CR19","doi-asserted-by":"publisher","first-page":"246","DOI":"10.18176\/jiaci.0479","volume":"31","author":"MJ Forjaz","year":"2021","unstructured":"Forjaz MJ, Ayala A, Caminoa M, Prior N, P\u00e9rez-Fern\u00e1ndez E, Caballero T. HAE-AS: a specific disease activity scale for hereditary angioedema with C1-inhibitor deficiency. J Investig Allergol Clin Immunol. 2021;31(3):246\u201352.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"3739_CR20","doi-asserted-by":"crossref","unstructured":"Magerl M, Martinez-Saguer I, Schauf L, Pohl S, Brendel K. The current situation of hereditary angioedema patients in Germany: results of an online survey. Front Med (Lausanne). 2024;10:1274397.","DOI":"10.3389\/fmed.2023.1274397"},{"issue":"4","key":"3739_CR21","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jaip.2022.12.021","volume":"11","author":"PH Li","year":"2023","unstructured":"Li PH, Pawankar R, Thong BY, Fok JS, Chantaphakul H, Hide M, et al. Epidemiology, management, and treatment access of hereditary angioedema in the Asia Pacific region: outcomes from an international survey. J Allergy Clin Immunol Pract. 2023;11(4):1253\u201360.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"3739_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jaci.2023.09.039","volume":"153","author":"D Honda","year":"2024","unstructured":"Honda D, Li PH, Jindal AK, Katelaris CH, Zhi YX, Thong BY, et al. Uncovering the true burden of hereditary angioedema due to C1-inhibitor deficiency: a focus on the Asia-Pacific region. J Allergy Clin Immunol. 2024;153(1):42\u201354.","journal-title":"J Allergy Clin Immunol"},{"issue":"18","key":"3739_CR23","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.3390\/healthcare11182509","volume":"11","author":"E Giacomini","year":"2023","unstructured":"Giacomini E, Leogrande M, Perrone V, Andretta M, Bacca M, Chinellato A, et al. Characteristics and drug utilization of patients with hereditary angioedema in Italy, a real-world analysis. Healthcare (Basel). 2023;11(18):2509.","journal-title":"Healthcare (Basel)"},{"issue":"4","key":"3739_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2500\/aap.2023.44.230026","volume":"44","author":"MA Riedl","year":"2023","unstructured":"Riedl MA, Hinds DR, Prince PM, Alvord TM, Dosenovic S, Abdelhadi JF, et al. Healthcare utilization of patients with hereditary angioedema treated with lanadelumab and subcutaneous C1-inhibitor concentrate. Allergy Asthma Proc. 2023;44(4):275\u201382.","journal-title":"Allergy Asthma Proc"},{"issue":"8","key":"3739_CR25","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1111\/all.14293","volume":"75","author":"M Maurer","year":"2020","unstructured":"Maurer M, Aberer W, Agondi R, Al-Ahmad M, Al-Nesf MA, Ansotegui I, et al. Definition, aims, and implementation of GA2LEN\/HAEi Angioedema Centers of reference and excellence. Allergy. 2020;75(8):2115\u201323.","journal-title":"Allergy"},{"key":"3739_CR26","unstructured":"REDCap. Research electronic data capture. https:\/\/www.project-redcap.org\/. Accessed 28 May 2025."},{"issue":"4","key":"3739_CR27","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/ced\/llad428","volume":"49","author":"AK Jindal","year":"2024","unstructured":"Jindal AK, Basu S, Tyagi R, Barman P, Sil A, Chawla S, et al. Delay in diagnosis is the most important proximate reason for mortality in hereditary angio-oedema: our experience at Chandigarh, India Clin Exp Dermatol. 2024;49(4):368\u201374.","journal-title":"Clin Exp Dermatol"},{"key":"3739_CR28","doi-asserted-by":"crossref","unstructured":"Boursiquot JN, Chapdelaine H, St-Pierre C, H\u00e9bert J. The disease burden of hereditary angioedema: insights from a survey in French-Canadians from Quebec. J Immunol Res. 2024;2024:3028617.","DOI":"10.1155\/2024\/3028617"},{"key":"3739_CR29","unstructured":"ACARE Network. Chronic Angioedema Registry (CARE). https:\/\/acare-network.com\/the-chronic-angioedema-registry-care\/. Accessed 28 May 2025."},{"issue":"5","key":"3739_CR30","doi-asserted-by":"publisher","first-page":"696","DOI":"10.2340\/00015555-3807","volume":"101","author":"ATH Brix","year":"2021","unstructured":"Brix ATH, Boysen HB, Weller K, Caballero T, Bygum A. Patient-reported outcome measures for angioedema: a literature review. Acta Derm Venereol. 2021;101(5):696.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"3739_CR31","doi-asserted-by":"publisher","first-page":"100792","DOI":"10.1016\/j.waojou.2023.100792","volume":"16","author":"J Raasch","year":"2023","unstructured":"Raasch J, Glaum MC, O\u2019Connor M. The multifactorial impact of receiving a hereditary angioedema diagnosis. World Allergy Organ J. 2023;16(6):100792.","journal-title":"World Allergy Organ J"},{"issue":"1","key":"3739_CR32","doi-asserted-by":"publisher","first-page":"e12328","DOI":"10.1002\/clt2.12328","volume":"14","author":"S Neisinger","year":"2024","unstructured":"Neisinger S, Sousa Pinto B, Ramanauskaite A, Bousquet J, Weller K, Metz M, et al. CRUSE\u00ae\u2014an innovative mobile application for patient monitoring and management in chronic spontaneous urticaria. Clin Transl Allergy. 2024;14(1):e12328.","journal-title":"Clin Transl Allergy"},{"key":"3739_CR33","unstructured":"HAE International (HAEi). https:\/\/haei.org\/. Accessed 28 May 2025."},{"key":"3739_CR34","unstructured":"HAEA. US Hereditary Angioedema Association (HAEA). https:\/\/www.haea.org\/. Accessed 28 May 2025."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03739-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03739-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03739-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:51:30Z","timestamp":1757310690000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03739-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3739"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03739-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TB was a speaker for, and\/or advisor for, and\/or has received research funding from Almirall, Aquestive, BioCryst, CSL Behring, GSK, Hexal, KalVista Pharmaceuticals, Medac, Novartis, Pharming, Roche, Sanofi-Aventis, Swixx BioPharma, and Takeda. FA declares no conflict of interest in relation to this work. AA reports conference travel support and\/or honoraria from BioCryst, Covis Pharma, CSL\u00a0Behring, GSK, and Takeda; and clinical trial support from Astria, BioCryst, Ionis Pharmaceuticals, KalVista Pharmaceuticals, Octapharma, Pharvaris, and Takeda. CVA is a clinical trial\/registry investigator for BioCryst, CSL Behring, Intellia, Novartis, Pharvaris, and Takeda. MAA-N declares no conflict of interest in relation to this work. SA declares no conflict of interest in relation to this manuscript. SA has conducted studies, and was an advisor and speaker, for ALK, Allakos, AstraZeneca, BioCryst, Blueprint, CSL\u00a0Behring, Leo Pharma, Moxie, Novartis, Pharvaris, Sanofi, Takeda, and Thermo Fisher. MA declares no conflict of interest in relation to this work. MA-A received speaker and advisory board honoraria from AstraZeneca, GSK, and Sanofi. RMA declares no conflict of interest in relation to this work. AB has participated as a speaker for Takeda, and in advisory boards for CSL Behring and Pint Pharma. IB-G is or recently was a speaker, advisor, and engaged in research and educational projects for, and\/or received research and consultancy grants from, BioCryst, CSL Behring, KalVista Pharmaceuticals, Novartis, Pharming, Pharvaris, and Takeda. LBo has consulted\/served as speaker for, engaged in research and educational projects with, or accepted travel grants from BioCryst, Blueprint, CSL Behring, GSK, KalVista Pharmaceuticals, Novartis, Pharvaris, and Takeda. LBr declares no conflict of interest in relation to this work. MB has received travel and congress bursaries and lecture fees from Pharming and Takeda. PJB declares no conflict of interests in relation to this work. PB has received consultancy grants from BioCryst, CSL Behring, Intellia, and Takeda. SDB has received speaker\/advisor fees and\/or research funding from Astria, Canadian Blood Services, CSL Behring, Green Cross, Grifols, Ionis Pharmaceuticals, KalVista Pharmaceuticals, Novartis, Octapharma, Pharvaris, Sanofi, Takeda, and WSIB. HC-N has received grants for consultation from CSL Behring, Pint Pharma, and Takeda, and has received speaker grants from Takeda. OCL declares no conflict of interest in relation to this work. TC is a speaker for Astria Therapeutics, BioMarin, CSL Behring, Grifols, Regeneron, and Takeda; and has received research and consultancy grants from Astria, CSL Behring, BioCryst, BioMarin, GSK, Intellia, Ionis, KalVista Pharmaceuticals, Pharvaris, and Takeda. TC is a member of the US Hereditary Angioedema Association Medical Advisory Board and Director of the ACARE International Angioedema Center at Penn State University in Hershey, PA, USA. ADD has received honoraria from BioCryst, CSL Behring, and Takeda for advisory board and speaking services; has received reasonable expenses to attend meetings and conferences from BioCryst and Pharming; and has been a sub-investigator for clinical trials sponsored by BioCryst Pharmaceuticals, Ionis Pharmaceuticals, and KalVista Pharmaceuticals. SDDJr has received payment or honoraria from AstraZeneca, Chiesi, and Novartis. SDDJr received support for attending meetings and\/or travel from CSL Behring, Sanofi, and Takeda. DF declares no conflict of interest in relation to this work. HF has received research grants from CSL Behring, Pharming, and Takeda; served as an advisor for BioCryst, CSL Behring, KalVista Pharmaceuticals, Intellia, Ionis Pharmaceuticals, ONO Pharmaceutical, Pharming, and Takeda; and participated in clinical trials\/registries for BioCryst, CSL Behring, KalVista Pharmaceuticals, Pharming, Pharvaris, and Takeda.\u00a0JSF has received speaker and\/or consultancy fees for presentations and advisory board participation from CSL Behring, Menarini, Novartis, Takeda, and Viatris. ASG has received research funding from Brazilian Entity of Research (CNPq) and Takeda\/Shire; and fees for educational activities or has acted as a consultant for Catalyst Pharmaceuticals, CSL Behring, KalVista Pharmaceuticals, MultiCare, Pharvaris, Pint Pharma, and Takeda. JG was a speaker and\/or advisor for, and\/or has received research funding from, BioCryst, CSL Behring, KalVista Pharmaceuticals, and Takeda. MGu has received honoraria for educational purposes from CSL Behring, Novartis, and Takeda; participated in advisory boards organized by CSL Behring, Novartis, and Takeda; and has received funding to attend conferences and educational events from CSL Behring, Novartis, Pharming, and Takeda. MGu is a clinical trial\/registry investigator for BioCryst, CSL Behring, Novartis, Pharming, Pharvaris, and Takeda; and is a researcher from the VHIR program for promoting research activities. MGo has received honoraria for educational purposes or medical advice from AbbVie, AstraZeneca, Leo Pharma, Lilly, Novartis, Pfizer, Sanofi, and Takeda. VG-P has participated in clinical trials\/registries for BioCryst, CSL Behring, KalVista Pharmaceuticals, Pharming, and Takeda. MH has received speaker\/consultancy fees from BioCryst, CSL Behring, KalVista Pharmaceuticals, Pharvaris, and Takeda. RH has received speaker\/consultancy fees and travel grants from, and\/or participated in advisory boards for, CSL Behring, Pharming, Shire, and Takeda; and has served as a Principal Investigator for clinical trials sponsored by BioCryst Pharmaceuticals, CSL Behring, KalVista Pharmaceuticals, Pharming, and Pharvaris Netherlands. AJ declares no conflict of interest in relation to this work. CHK has received speaker\/consultancy fees for presentations and advisory board participation from CSL Behring, KalVista Pharmaceuticals, Pharvaris, and Takeda. SK declares no conflict of interest in relation to this work. TK is or recently was a speaker and\/or advisor for, and\/or has received research funding from, BioCryst, Blueprint, CSL Behring, HAL Allergy, KalVista Pharmaceuticals, Kiniksa, Novartis, Pharvaris, Sanofi-Aventis, and Takeda\/Shire. EL is or recently was a speaker and\/or advisor for, and\/or has received research funding from, CSL Behring, Generium, Novartis, Octapharma, and Takeda\/Shire. JILS declares no conflict of interest in relation to this work. RLB has received speaker\/consultancy fees from, and\/or participated in advisory boards for, BioCryst, CSL Behring, Novartis, Pharming, and Takeda; and is\/has been a clinical trial\/registry investigator for BioCryst, Ionis, KalVista Pharmaceuticals, Pharvaris, and Takeda. HM declares no conflict of interest in relation to this work. MMet has received honoraria as a speaker and\/or advisor from AbbVie, ALK-Abell\u00f3, Almirall, Amgen, Argenx, AstraZeneca, Bayer, Beiersdorf, Celldex, Celltrion, Escient, Galderma, GSK, Incyte, Jasper, Novartis, Pfizer, Pharvaris, Regeneron, Sanofi, Teva, Third Harmonic Bio, and Vifor. IN is or recently was a speaker for Sanofi and Takeda. NTM declares no conflict of interest in relation to this work. SN declares no conflict of interest in relation to this work. CASP declares no conflict of interest in relation to this work. GP has received speaker fees, and\/or consultancy fees, and\/or travel support from CSL Behring, Swixx BioPharma, and Takeda. JP is or recently was a speaker and\/or advisor for, and\/or has received research funding from, Astria, BioCryst, CSL Behring, Glenmark, Novartis, Pharming, Pharvaris, Sanofi\/Regeneron, and Takeda. MPLF declares no conflict of interest in relation to this work. NRF declares no conflict of interest in relation to this work. BES declares no conflict of interest in relation to this work. FSS reports personal fees and other from AstraZeneca, CSL Behring, GSK, Novartis, and Takeda. MS has received grants and\/or fees as a speaker from BioCryst, CSL Behring, KalVista Pharmaceuticals, Pharming, and Takeda; and is a clinical trial investigator for BioCryst, Ionis, Isis, KalVista Pharmaceuticals, and Pharvaris. ST was a speaker and\/or advisor for CSL Behring and Takeda; and participated in clinical trials\/registries for BioCryst, CSL Behring, Ionis Pharmaceuticals, and Takeda. AV has received honoraria for educational lectures, consultancy, sponsorship for educational meetings, and research projects from AstraZeneca, Astria Pharmaceuticals, Berlin-Chemie\/Menarini Group, CSL Behring, Ewopharma, Ionis, KalVista Pharmaceuticals, Novartis, Organon, Pharming Group N. V., Pharvaris, Takeda\/Shire, SOBI, Stallergenes Greer, and Teva. CW has received honoraria for scientific lectures from Abbott, AstraZeneca, GSK, Menarini, Novartis, Sanofi, and Takeda; and research support from Abbott and Sanofi. JCYW declares no conflict of interest in relation to this work. EY declares no conflict of interest in relation to this work. YL is a full-time employee of CSL Behring LLP and shareholder of CSL Limited. CN is a full-time employee of CSL Behring AG and shareholder of CSL Limited. MMau was a speaker and\/or advisor for, and\/or received research funding from, Astria, BioCryst, CSL Behring, KalVista Pharmaceuticals, Pharvaris, and Takeda. MMag has received financial support from CSL Behring for acting as a study center investigator during the conduct of the study and personal fees from BioCryst, CSL Behring, KalVista Pharmaceuticals, Novartis, Octapharma, Pharming Technologies, and Takeda\/Shire. PHL was a speaker and\/or advisor for, and\/or has received research funding from, CSL\u00a0Behring, KalVista Pharmaceuticals, Pharvaris, and Takeda.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"383"}}